Literature DB >> 8433562

LDL stimulates mesangial fibronectin production and chemoattractant expression.

B H Rovin1, L C Tan.   

Abstract

Hyperlipidemia has been associated with glomerulosclerosis and a glomerular monocyte infiltrate in models of progressive renal insufficiency. The pathogenesis of hyperlipidemia-induced renal injury remains unknown. We postulated that the effect of hyperlipidemia may be mediated through LDL-induced activation of mesangial cells, which have recently been shown to possess LDL receptors. To test this hypothesis, cultured human mesangial cells were co-incubated with human LDL. Monolayers treated with LDL demonstrated a greater level of tissue culture supernatant fibronectin than control mesangial cells. This correlated with enhanced expression of fibronectin mRNA in LDL-treated mesangial cells. Additionally, LDL conditioning of mesangial cells caused a dose- and time-dependent increase in the expression of monocyte chemoattractant protein-1 mRNA, a monocyte specific chemotactic factor, as well as an increase in the monocyte chemotactic activity of mesangial supernatants. Thus, the deleterious effects of hyperlipidemia on the kidney may be mediated by the mesangial cell through an increase in production of mesangial matrix and recruitment of inflammatory cells to the glomerulus.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8433562     DOI: 10.1038/ki.1993.35

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  14 in total

Review 1.  Anti-fibrosis therapy and diabetic nephropathy.

Authors:  Anil Karihaloo
Journal:  Curr Diab Rep       Date:  2012-08       Impact factor: 4.810

Review 2.  HMG-CoA reductase inhibitors and the kidney.

Authors:  Vito M Campese; Bassel Hadaya; Josephine Chiu
Journal:  Curr Hypertens Rep       Date:  2005-10       Impact factor: 5.369

Review 3.  Extracellular matrix and the kidney.

Authors:  P N Furness
Journal:  J Clin Pathol       Date:  1996-05       Impact factor: 3.411

Review 4.  New pharmacological treatments for improving renal outcomes in diabetes.

Authors:  Anne-Emilie Declèves; Kumar Sharma
Journal:  Nat Rev Nephrol       Date:  2010-05-04       Impact factor: 28.314

Review 5.  Dyslipidemia, kidney disease, and cardiovascular disease in diabetic patients.

Authors:  Szu-chi Chen; Chin-Hsiao Tseng
Journal:  Rev Diabet Stud       Date:  2013-08-10

6.  Low-density lipoproteins enhance transforming growth factor-beta 1 (TGF-beta 1) and monocyte chemotactic protein-1 (MCP-1) expression induced by cyclosporin in human mesangial cells.

Authors:  S Di Paolo; G Grandaliano; L Gesualdo; E Ranieri; F P Schena
Journal:  Clin Exp Immunol       Date:  1999-08       Impact factor: 4.330

7.  Endothelin receptor A-specific stimulation of glomerular inflammation and injury in a streptozotocin-induced rat model of diabetes.

Authors:  M A Saleh; E I Boesen; J S Pollock; V J Savin; D M Pollock
Journal:  Diabetologia       Date:  2010-12-30       Impact factor: 10.122

Review 8.  Arterial hypertension and hyperlipidemia as determinants of glomerulosclerosis.

Authors:  H J Gröne; A K Walli; E F Gröne
Journal:  Clin Investig       Date:  1993-10

9.  The leaf extract of Ginkgo Biloba L. suppresses oxidized LDL-stimulated fibronectin production through an antioxidant action in rat mesangial cells.

Authors:  Satoshi Akiba; Masahiro Chiba; Yuki Mukaida; Akira Tamura; Takashi Sato
Journal:  Br J Pharmacol       Date:  2004-05-17       Impact factor: 8.739

10.  Preventive effect of cerivastatin on diabetic nephropathy through suppression of glomerular macrophage recruitment in a rat model.

Authors:  T Ota; T Takamura; H Ando; E Nohara; H Yamashita; K Kobayashi
Journal:  Diabetologia       Date:  2003-05-27       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.